Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer that has recurred after previous treatment and that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or doctor's choice of standard-of-care (SOC) cetuximab or bevacizumab + chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony przez biopsję lub cytologię rak gruczołowy jelita grubego, który powrócił, nie może być operacyjnie usunięty lub rozprzestrzenia się na inne części ciała
- •Gen KRAS i NRAS bez mutacji (typu dzikofilm) potwierdzone badaniem genetycznym
- •Wcześniej leczony maksymalnie jedną linią systemowej chemioterapii na raka nieoperacyjnego, z potwierdzonym postępem choroby
- •Możliwość otrzymywania chemioterapii mFOLFOX6 lub FOLFIRI zgodnie ze wskazaniami medycznymi
✗ Disqualifies
- •Mutacja BRAF V600 w komórkach nowotworu
- •Niestabilność mikrosatellitów lub defekt naprawy błędów DNA w guzie
- •Pozytywny lub wzmocniony status HER2
- •Wcześniejsze leczenie lekami skierowanymi na receptor EGFR (cetuximab, panitumumab i inne)
- •Wcześniejsze otrzymywanie irynotekan (dla uczestników przydzielonych do FOLFIRI) lub oksaliplatyny (dla uczestników przydzielonych do FOLFOX)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 26, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
PanOncology
Manati, Puerto Rico
Trial contact
Genmab Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/27/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.